Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

Oslo, Norway, 15 July 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces the start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab. All safety reviews during the dose escalation phase have been completed with no Dose Limiting Toxicities (DLT) reported and the five US hospital sites are now open for further recruitment.

This phase I/II trial investigates the safety, biologic and anti-tumor activity of ONCOS-102 in combination with Imfinzi (durvalumab, anti-PD-L1) in patients with advanced peritoneal malignancies who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian or colorectal cancer.

The sponsor of the trial is Ludwig Institute for Cancer Research with coordination and funding support from the Cancer Research Institute.

For further information regarding the trial, please visit ClinicalTrials.Gov.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It is used as a therapeutic cancer vaccine and has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around end 2019 – early 2020.